---
title: "SHINEWAY PHARM released its interim results, with a profit of 615 million yuan, a year-on-year decrease of 1.89%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254728885.md"
description: "SHINEWAY PHARM released its mid-term results for 2025, with revenue of 1.653 billion yuan, a year-on-year decrease of 20.8%; profit for the period was 615 million yuan, a year-on-year decrease of 1.89%. Basic earnings per share were 0.81 yuan, and an interim dividend of 0.11 yuan per share is proposed. The gross profit margin fell from 75.3% to 72.2%, mainly due to rising raw material costs. Despite the decline in sales and gross profit margin, net profit only slightly decreased by 1.9%, and the net profit margin rose to 37.2%. Oral products accounted for 65.8% of total sales"
datetime: "2025-08-27T04:07:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254728885.md)
  - [en](https://longbridge.com/en/news/254728885.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254728885.md)
---

# SHINEWAY PHARM released its interim results, with a profit of 615 million yuan, a year-on-year decrease of 1.89%

According to the Zhitong Finance APP, SHINEWAY PHARM (02877) released its interim results for 2025, with revenue of RMB 1.653 billion, a year-on-year decrease of 20.8%; profit for the period was RMB 615 million, a year-on-year decrease of 1.89%; basic earnings per share were 81 cents; and an interim dividend of 11 cents per share is proposed.

The announcement stated that during the period, the group's gross profit margin decreased from 75.3% in the same period last year to 72.2%. This was mainly due to the rise in raw material procurement costs and the impact of centralized procurement on drug prices.

With the overall sales and gross profit margin declining during the period, the group's operating profit for the first six months of 2025 also decreased compared to the same period last year. However, due to an increase in investment income and the group's efforts to control costs and improve efficiency, selling and distribution costs and administrative expenses decreased by approximately 20.7% and 12.9%, respectively, compared to the same period last year, resulting in a slight decrease of 1.9% in net profit compared to the same period last year, while the net profit margin increased from 30.0% to 37.2%.

The group continues to focus on expanding its oral formulation as a key development strategy. In the first six months of 2025, oral products accounted for 65.8% of total sales, while injectable products accounted for 34.2% of total sales.

Total sales of injectable products decreased by 27.4% compared to the same period last year, mainly due to sales of Qingkailing injection and Shenmai injection decreasing by 50.1% and 21.0%, respectively, compared to the same period last year, while sales of several injectable products such as Shuxue Ning injection, Guanxin Ning injection, and Danshen injection also decreased by 6.3%, 9.6%, and 24.6%, respectively

### Related Stocks

- [02877.HK](https://longbridge.com/en/quote/02877.HK.md)

## Related News & Research

- [PegBio appoints Yik Lam Liao as independent director, names her audit chair](https://longbridge.com/en/news/290682093.md)
- [Veidekke CEO Bengtsson buys NOK 992,952 in shares](https://longbridge.com/en/news/290535348.md)
- [CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity Awards](https://longbridge.com/en/news/290618548.md)
- [SoftOx Solutions shareholders approve 2025 annual accounts, report](https://longbridge.com/en/news/290674267.md)
- [Samsung Electronics plans 90 trln won share buyback, Yonhap reports](https://longbridge.com/en/news/290629490.md)